More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

키워드

참고문헌 (15)

1. "Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015"[URL]
2. Fabrizi F, "Hepatitis C virus infection increases the risk of developing chronic kidney disease : a systematic review and meta-analysis", Dig Dis Sci, 60, pp.3801~3813 (2015)
3. Chen YC, "Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors : a 6-year nationwide cohort study across Taiwan", BMC Nephrol, 14, pp.187~ (2013)
4. Fabrizi F, "Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?", J Viral Hepat, 19, pp.601~607 (2012)
5. Goodkin DA, "Hepatitis C infection is very rarely treated among hemodialysis patients", Am J Nephrol, 38, pp.405~412 (2013)
6. Gilead Sciences, "Sofosbuvir" (2013), Gilead Sciences
7. Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatmentexperienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease(the C-SURFER study) : a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)
8. Youn Jae Lee, "An integrated analysis of elbasvir", grazoprevir in Korean patients with hepatitis C virus genotype 1b infection, 2019, pp.25(4), 400~407[DOI]
9. Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)
10. Lawitz E, "Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment : a multicentre, phase 2b, non-randomised, open-label study", Lancet Gastroenterol Hepatol, 5, pp.918~926 (2020)
11. Borgia SM, "Sofosbuvir", velpatasvir for 12 weeks in hepatitis C virusinfected patients with end-stage renal disease undergoing dialysis, 2019, pp.71, 660~665
12. Mehrotra R, "The current state of peritoneal dialysis", J Am Soc Nephrol, 27, pp.3238~3252 (2016)
13. Desmond Y. H. Yap, "Use of glecaprevir", pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment, 2020, pp.26(4), 554~561[DOI]
14. Backus LI, "Direct-acting antiviral sustained virologic response : impact on mortality in patients without advanced liver disease", Hepatology, 68, pp.827~838 (2018)
15. Backus LI, "Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease", Hepatology, 69, pp.487~497 (2019)

관련 논문AI추천